The European Commission has approved delaminid (Deltyba) for use in patients suffering from MDR-TB.
TB Alliance announces STAND, a Phase 3 Clinical Trial aimed at shortening the duration of treatment for drug-sensitive and MDR-TB.
The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. Its range and ability to inhibit multiple targets, makes SQ109 an attractive broad-based antimicrobial compound that also reduces the likelihood of resistance developing in bugs.
TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.
Researchers at EPFL and the Bach Institute in Moscow have discovered an antibiotic effective against sensitive and MDR-tuberculosis. With support from EPFL, the researchers have created Innovative Medicines for Tuberculosis (iM4TB), an organization to help usher the new antibiotic to market.
The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.
This week we highlight a study by Richard E. Lee et al showing that semisynthetic antibiotic, spectinamides, is effective against drug sensitive and resistant tuberculosis. Additional links related to this study and general TB R&D are included.
A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.
This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress made to date. Additional links to news coverage of the report are included
In a significant finding for millions of TB patients, researchers have recently shown that adjunct chemotherapy with verapamil can accelerate tuberculosis treatment in mouse model.